Yong Ben's most recent trade in BridgeBio Oncology Therapeutics Inc. was a trade of 1,047 Common Stock done at an average price of $7.8 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc | Yong Ben | Chief Med & Dev Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.80 per share. | 01 Jul 2026 | 1,047 | 44,576 | - | 7.8 | 8,167 | Common Stock |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 12,300 | 12,300 | - | - | Stock options (right to buy) | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 3,800 | 11,383 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| BridgeBio Oncology Therapeutics Inc | Yong Ben | Chief Med & Dev Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.03 per share. | 01 Apr 2026 | 1,047 | 45,623 | - | 9.0 | 9,454 | Common Stock |
| BridgeBio Oncology Therapeutics Inc | Yong Ben | Chief Med & Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 210,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Oncology Therapeutics Inc | Yong Ben | Chief Med & Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 46,670 | 46,670 | - | 0 | Common Stock | |
| BridgeBio Oncology Therapeutics Inc | Yong Ben | Chief Med & Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 357,177 | 357,177 | - | - | Stock Option (Right to Buy) | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 16,000 | 16,000 | - | - | Stock options (right to buy) | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 4,800 | 7,583 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Corbus Pharma Holdings Inc | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 5,307 | 5,307 | - | - | Stock Option(right to buy) |